ClinicalTrials.gg
CompletedNCT06750276BORANAUpdated Jul 6, 2026Results posted

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

A Phase 2 interventional study of AZD2389 in Liver Fibrosis and Hepatic Cirrhosis, sponsored by AstraZeneca. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
6th of 11
40 · median 40
Started
2024
with 2 others
Phase 2
6 of 11
1 open now
Registered
6th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 6th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 2, and was the 6th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body

Read the detailed description

Study details include:

The study duration will be up to 63 days (9 weeks).

  • 1 or 2 screening visits (up to 28 days before treatment)
  • 28 days of treatment including 5 clinic visits
  • Week 1: 24-hour in-clinic stay (Day 1)
  • Week 2: Outpatient clinic visit (Day 7)
  • Week 3: Outpatient clinic visit (Day 14)
  • Week 4: Telephone visit (Day 21)
  • Week 5: 24 to 48-hour in-clinic stay (Day 28)
  • Week 6: Follow-up visit (Day 35) Disclosure Statement: The study consists of two cohorts, each with a parallel-group design and two arms, with participants blinded to treatment allocation.

Number of Participants:

The study will randomise approximately 36 participants in total. Cohort A: Approximately 75 participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. Cohort B: Approximately 75 participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo

03

Conditions studied

  • Liver Fibrosis
  • Hepatic Cirrhosis

Browse trials for

Keywords

  • Liver Fibrosis
  • Hepatic Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusions:

  • Males/females aged ≥ 18 years
  • Indications: Presumed MASH (cohort A) or other steatotic liver disease (cohort B) with fibrosis
  • No significant change in weight over the last 6 months
  • Barrier use by males
  • Capable of
  • Judged to be suitable for study by investigator

Key exclusions:

  • A condition that could put the participant at risk, influence the participant's ability to participate in the trial, interfere with evaluation of the study intervention or affect the interpretation of the results
  • Other causes of liver disease which are not the principal inclusion criteria for each cohort
  • Significant elevations in liver blood tests or \<140 x10\^9/L
  • Decompensated liver disease, hepatobiliary cancer or listing for liver transplantation
  • Bleeding disorders or major bleeding risk
  • infection or infection
  • cardiovascular (e.g. severe ischaemic heart disease, severe heart failure or cardiac dysrhythmia) or cerebrovascular disease within the past 3 months
  • Stage 2 hypertension
  • \<60ml/min/1.73m2
  • Clinically significant gastrointestinal disease which can affect the interpretation of pharmacokinetic, safety, and tolerability data
  • Skin disorders or ongoing wound healing
  • Psychiatric disorders which may negatively affect participation in the trial.
  • Females of
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Other
    Cohort A

    Participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.

    Drug: AZD2389

  • Other
    Cohort B

    Participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.

    Drug: AZD2389

Interventions

  • Doses of AZD2389 or placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)

    The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria.

    Time frame: From screening up to and including Day 35

  2. Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)

    The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities.

    Time frame: From Screening up to and including Day 35

Secondary outcomes

  1. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration

    Time frame: Day 1 and Day 28

  2. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration

    Time frame: Day 1 and Day 28

  3. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life

    Time frame: Day 1 and Day 28

  4. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28.

    Time frame: Day 1 and Day 28

  5. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant

    Time frame: Day 1 and Day 28

  6. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution

    Time frame: Day 1 and Day 28

  7. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance

    Time frame: Day 1 and Day 28

  8. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve

    Time frame: Day 28

  9. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax

    Time frame: Day 28

  10. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24)

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine

    Time frame: Day 1 and Day 28

  11. Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24)

    The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine

    Time frame: Day 1 and Day 28

  12. Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo.

    Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) \*100. FAP=Fibroblast Activating Protein

    Time frame: Day 28

07

Results

Posted Jul 6, 2026

Participant flow

A total of 95 participants were screened for the study at 9 centres (1 in the UK and 8 in the US).

Participant flow — Overall Study
MilestoneCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Started148126
Completed148126
Not completed0000

Outcome measures

SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · nmol/L
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax
nmol/LCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 12045 ± 57.39—1902 ± 47.63—
Day 281884 ± 60.65—1730 ± 63.54—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration

Time frame:
Day 1 and Day 28
Reported as:
Median · hour
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax
hourCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 11.00 (0.50 to 4.00)—1.00 (0.50 to 4.00)—
Day 281.00 (0.50 to 4.00)—1.00 (0.50 to 2.00)—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · hour
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z
hourCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 13.801 ± 36.42—5.545 ± 58.67—
Day 285.331 ± 57.86—5.527 ± 64.06—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28.

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · h*nmol/L
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau
h*nmol/LCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
AUClast: Day 17339 ± 42.79—6052 ± 32.89—
AUClast: Day 287529 ± 51.51—5482 ± 34.29—
AUCinf: Day 17409 ± 42.88—6480 ± 39.06—
AUC0-24h: Day 17341 ± 42.76—6112 ± 32.58—
AUC0-24h: Day 287301 ± 48.45—5374 ± 33.20—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · 1/h
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z
1/hCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 10.1824 ± 36.42—0.1250 ± 58.67—
Day 280.1300 ± 57.86—0.1254 ± 64.06—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · L
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F
LCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 1215.8 ± 44.25—360.0 ± 44.45—
Day 28307.2 ± 84.33—432.8 ± 68.96—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · L/h
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR
L/hCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
CL/F: Day 139.36 ± 42.88—45.00 ± 39.06—
CL/F: Day 2839.95 ± 48.45—54.27 ± 33.20—
CLR: Day 18.492 ± 231.5—16.41 ± 35.30—
CLR: Day 2811.13 ± 75.23—17.05 ± 194.2—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve

Time frame:
Day 28
Reported as:
Geometric mean · Ratio
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC
RatioCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC0.9853 ± 28.59—0.8293 ± 61.87—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax

Time frame:
Day 28
Reported as:
Geometric mean · Ratio
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax
RatioCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Rac AUC: Day 280.9945 ± 28.76—0.8792 ± 54.94—
Rac Cmax: Day 280.9212 ± 40.86—0.9095 ± 72.69—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24)

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · mg
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24)
mgCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 122.53 ± 257.8—37.35 ± 33.89—
Day 2830.81 ± 95.26—26.89 ± 100.5—
SecondaryPlasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24)

The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine

Time frame:
Day 1 and Day 28
Reported as:
Geometric mean · % of fraction of dose unchanged
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24)
% of fraction of dose unchangedCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Day 118.78 ± 257.8—31.12 ± 33.89—
Day 2825.67 ± 95.26—22.41 ± 100.5—
PrimaryNotable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)

The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria.

Time frame:
From screening up to and including Day 35
Reported as:
Count of participants · Participants
Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)
ParticipantsCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)0 ± 00 ± 00 ± 00 ± 0
PrimaryClinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)

The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities.

Time frame:
From Screening up to and including Day 35
Reported as:
Count of participants · Participants
Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)
ParticipantsCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)0 ± 00 ± 00 ± 00 ± 0
SecondaryInhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo.

Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) \*100. FAP=Fibroblast Activating Protein

Time frame:
Day 28
Reported as:
Geometric least squares mean · % of change in FAP activity
Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo.
% of change in FAP activityCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo.-80.0122 (-87.6644 to -67.6131)10.3140 (-43.5942 to 115.7436)-83.3455 (-91.2626 to -68.2546)-10.3764 (-64.0341 to 123.3336)
Statistical analysis
  • Cohort A - AZD2389 vs Cohort A - Placebo · Mixed Models Analysis · p = <0.001 · Geometric ls mean ratio %change: -81.8810 · 95% CI -92.0724 to -58.5880Percent change is calculated as (Geometric LS mean ratio - 1) x 100.
  • Cohort B - AZD2389 vs Cohort B - Placebo · Mixed Models Analysis · p = 0.004 · Geometric ls mean ratio %change: -81.4173 · 95% CI -93.9320 to -43.0919Percent change is calculated as (Geometric LS mean ratio - 1) x 100.

Adverse events

Collected over From screening to Day 35 up to 63 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A - AZD23890/14 (0%)0/14 (0%)6/14 (42.9%)
Cohort A - Placebo0/8 (0%)0/8 (0%)3/8 (37.5%)
Cohort B - AZD23890/12 (0%)0/12 (0%)1/12 (8.3%)
Cohort B - Placebo0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - Placebo
DyspepsiaGastrointestinal disorders0/140/80/121/6
Electrocardiogram qt prolongedInvestigations0/141/80/120/6
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/141/80/120/6
VomitingGastrointestinal disorders0/141/80/120/6
RhinitisInfections and infestations0/141/80/120/6
Blood creatine phosphokinase increasedInvestigations0/140/81/120/6
HeadacheNervous system disorders1/140/80/120/6
DysuriaRenal and urinary disorders1/140/80/120/6
PruritusSkin and subcutaneous tissue disorders1/140/80/120/6
DiarrhoeaGastrointestinal disorders1/140/80/120/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - PlaceboTotal
Mean58.9 ± 12.857.5 ± 10.254.8 ± 7.155.5 ± 10.256.9 ± 10.2
Age, Customized
Age, Customized(Participants)Cohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - PlaceboTotal
18 - < 658612430
>= 65620210
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - PlaceboTotal
Female742417
Male7410223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - PlaceboTotal
Hispanic or Latino9811634
Not Hispanic or Latino50106
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - PlaceboTotal
American Indian or Alaska Native00101
Asian00000
Black or African American10102
Native Hawaiian or other Pacific Islander00000
Not reported00000
Other00000
White13810637
Region of Enrollment
Region of Enrollment(Participants)Cohort A - AZD2389Cohort A - PlaceboCohort B - AZD2389Cohort B - PlaceboTotal
USA14812640
08

Study locations

9 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Rialto, California 92377, United States
  • Research Site
    Atlanta, Georgia 30349, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    Houston, Texas 77079, United States
  • Research Site
    San Antonio, Texas 78215, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Juan, 00927, Puerto Rico
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jul 2025, 7 months.

Results were first posted in Jul 2026, 11 months after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 7 months is below that.

Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 27, 2024
StartActual
Dec 6, 2024
Primary completionActual
Jul 28, 2025
CompletionActual
Jul 28, 2025
Results first posted
Jul 6, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06750276
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Dec 6, 2024
Primary completion
Jul 28, 2025
Completion
Jul 28, 2025
Results posted
Jul 6, 2026
Last update
Jul 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion